根治性肾输尿管切除术前诊断性输尿管镜检查风险分层策略的十年生存结局:单中心观察性回顾性队列研究
该单中心回顾性队列研究纳入422例确诊上尿路尿路上皮癌并接受根治性肾输尿管切除术的患者,中位随访9.2年,5年和10年癌症特异性生存率分别为70.5%和67.1%。诊断性输尿管镜检查与直接手术组的总生存和癌症特异性生存相似,但直接手术组的膀胱内无复发生存更优(HR 1.94,95%CI 1.19-3.17,P=0.008)。作者建议采用风险分层策略,仅在模棱两可的病例中行诊断性输尿管镜检查。
要点
- 5年和10年癌症特异性生存率分别为70.5%和67.1%。
- 诊断性输尿管镜与直接手术组的总生存和癌症特异性生存相似。
- 直接手术组的膀胱内无复发生存更优(HR 1.94,P=0.008)。
核心结论
- 本单中心回顾性队列研究报告了根治性肾输尿管切除术后中位随访9.2年的长期肿瘤学结局,可作为咨询接受该手术患者的参考标准。
- 根治性肾输尿管切除标本的分期和分级是仅有的两个似乎对长期癌症特异性生存和总生存产生不利影响的研究因素。
- 结果表明,在根治性肾输尿管切除术前接受诊断性输尿管镜检查的患者膀胱内复发风险增加近两倍。
- 然而,既往输尿管镜检查似乎不会对长期癌症特异性生存和总生存产生不利影响。
- 作者建议采用风险分层方法,仅在模棱两可的病例中提供诊断性输尿管镜检查。
研究设计与样本
- 单中心观察性回顾性队列研究,分析英国三级转诊中心前瞻性维护数据库中自述连续接受根治性肾输尿管切除术的疑似上尿路尿路上皮癌患者。
- 共422例确诊上尿路尿路上皮癌患者接受根治性肾输尿管切除术,中位(四分位距)随访9.2(5.6-12.7)年。
- 主要结局为5年和10年癌症特异性生存;次要结局包括总生存、无复发生存、既往诊断性输尿管镜对总生存、癌症特异性生存和膀胱内无复发生存的影响以及膀胱内复发的预测因素。
- 使用Kaplan-Meier法计算生存函数,采用Cox比例风险回归模型进行单因素/多因素生存分析,统计显著性设定为P<0.05。
主要发现
- 5年和10年癌症特异性生存率分别为70.5%(95%CI 65.9-74.9)和67.1%(95%CI 62.4-71.6)。
- 诊断性输尿管镜队列与直接根治性肾输尿管切除队列的总生存相似(HR 1.04,95%CI 0.78-1.38;P=0.46)。
- 诊断性输尿管镜队列与直接根治性肾输尿管切除队列的癌症特异性生存相似(HR 0.96,95%CI 0.68-1.34;P=0.81)。
- 直接根治性肾输尿管切除队列的膀胱内无复发生存更优(HR 1.94,95%CI 1.19-3.17;P=0.008)。
- 多因素分析中,既往输尿管镜检查、T2分期、近端输尿管肿瘤和膀胱癌病史是异时性膀胱复发的预测因素。
关键数值与推荐
- 5年癌症特异性生存率为70.5%(95%CI 65.9-74.9),10年癌症特异性生存率为67.1%(95%CI 62.4-71.6)。
- 总生存:诊断性输尿管镜队列 vs 直接根治性肾输尿管切除队列 HR 1.04(95%CI 0.78-1.38;P=0.46)。
- 癌症特异性生存:诊断性输尿管镜队列 vs 直接根治性肾输尿管切除队列 HR 0.96(95%CI 0.68-1.34;P=0.81)。
- 膀胱内无复发生存:直接根治性肾输尿管切除队列优于诊断性输尿管镜队列,HR 1.94(95%CI 1.19-3.17;P=0.008)。
临床怎么用
- 作者建议采用风险分层方法,仅在模棱两可的病例中提供诊断性输尿管镜检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the long-term oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU) and the impact of diagnostic ureteroscopy (URS) on survival outcomes. MATERIALS AND METHODS: A retrospective analysis of all consecutive patients undergoing RNU for suspected UTUC at a UK tertiary referral centre from a prospectively maintained database was conducted. The primary outcome measures were 5- and 10-year cancer-specific survival (CSS). The secondary outcomes were: overall survival (OS), recurrence-free survival (RFS), impact of prior diagnostic URS on OS, CSS and intravesical RFS (intravesical-RFS), and predictors of intravesical recurrence. Statistical analysis was performed in R using the 'survminer' and 'survival' packages. The Kaplan-Meier method was used to calculate survival functions and these were expressed in graphical form. Uni-/multivariate survival analyses were performed using the Cox proportional hazard regression model. Statistical significance in this study was set at P < 0.05. RESULTS: A total of 422 patients underwent RNU with confirmed UTUC. The median (interquartile range) follow-up of patients with confirmed UTUC was 9.2 (5.6-12.7) years. The 5- and 10-year CSS rates were 70.5% (95% confidence interval [CI] 65.9-74.9) and 67.1% (95% CI 62.4-71.6), respectively. OS (HR 1.04 [95% CI 0.78-1.38]; P = 0.46) and CSS (HR 0.96 [95% CI 0.68-1.34]; P = 0.81) were similar in the diagnostic URS and the direct RNU cohorts. intravesical RFS was superior for the direct RNU cohort (HR 1.94 [95% CI 1.19-3.17]; P = 0.008). In multivariate analysis, prior URS, T2 stage, proximal ureter tumour and bladder cancer history were predictors of metachronous bladder recurrence. CONCLUSION: This single-centre retrospective cohort study reports the long-term oncological outcomes of RNU with a median follow-up of 9.2 years, serving as a reference standard in counselling patients undergoing RNU. Stage and grade of the RNU specimen were the only two studied factors that appeared to adversely impact long-term CSS and OS. Our results suggest that the risk of intravesical recurrence is increased nearly twofold in patients who have undergone diagnostic URS prior to RNU. Prior URS, however, does not appear to adversely impact long-term CSS and OS. The authors suggest that a risk-stratified approach be adopted, wherein diagnostic URS is offered only in equivocal cases.
引用
- Veeratterapillay R, Geraghty R, Pandian R, et al. Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study. BJU Int. 2021. PMID: 34726325. doi:10.1111/bju.15627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。